Rezolute Shares Collapse 90% After Late-Stage Study Misses Primary Endpoint

Rezolute shares plunged 90% in premarket trading after its Phase 3 trial for ersodetug failed to show meaningful benefit in treating congenital hyperinsulinism. source: https://tokenist.com/rezolute-shares-collapse-90-after-late-stage-study-misses-primary-endpoint/?utm_source=rss&utm_medium=rss&utm_campaign=rezolute-shares-collapse-90-after-late-stage-study-misses-primary-endpoint